The story of Sildenafil presents a nuanced case for observers in the pharmaceutical sector. While initially a blockbuster success, producing vast sums, the patent lapse and the subsequent flood of cheaper alternatives have drastically affected revenue. This raises questions about the ongoing viability of related therapeutic projects and suggests th